JPRN-UMIN000044213
Recruiting
未知
A prospective observational study to investigate the safety of SARS-Cov-2 vaccine for patients with advanced lung cancer who are treated with immune checkpoint inhibitor. - Association between immune related adverse events and novel coronavirus vaccine for advanced lung cancer patients
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital0 sites100 target enrollmentMay 14, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients that doctor in charge consider them inappropriate as a subject Patients who had already infected with COVID\-19
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A prospective observational study to investigate the effect of rehabilitation for cancer patients in palliative care units in Japan: a pilot-feasibility studyJPRN-UMIN000034560Ashiya Municipal Hospital50
Completed
Not Applicable
A prospective observational study to investigate the relationship between instability of glucose variability with age and diabetes-related complications or disorders in Japanese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000044304Hokkaido University Hospital200
Completed
Not Applicable
Aetiology of preoperative anaemia in cardiac surgeryPreoperative anaemiaHaematological DisordersISRCTN49461366Papworth Hospital (UK)200
Completed
Not Applicable
A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)ung cancerJPRN-UMIN000043918Iwakuni Clinical Center500
Recruiting
Not Applicable
A prospective observational study to investigate real-world IMmunogenicity of theraPeutic Antibodies and to identify faCTors responsible for the interindividual variabilityJPRN-jRCT1011220023Fukudo Masahide300